Business Context and Reporting Period
This Form 8-K Current Report was filed by Rhythm Pharmaceuticals, Inc. on August 4, 2023, with the earliest event reported on the same date. The filing addresses corporate governance changes under Item 5.02 regarding the departure of a senior officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Departure of Chief Accounting Officer: William T. Roberts was notified on August 4, 2023, of the termination of his employment, effective August 11, 2023.
- Appointment of Principal Accounting Officer: On August 8, 2023, the Board of Directors designated Christopher German, Executive Director and Corporate Controller, as the new principal accounting officer, effective August 11, 2023.
Management Commentary and Background
Christopher German, 52, brings over 20 years of experience in financial reporting, accounting, treasury, and audit from global, publicly-traded life sciences, technology, and manufacturing companies. His recent experience includes serving as Corporate Controller at Oncorus, Inc. (May 2021 to March 2023) and Repligen Corporation (July 2018 to March 2021). He holds a B.S. in Accounting from Lehigh University and is a Certified Public Accountant. In connection with his appointment, Mr. German will enter into the Company's standard indemnification agreement for directors and officers.
Investor Verification Checklist
- Verify the effective date of the leadership transition (August 11, 2023).
- Confirm Christopher German's prior roles at Oncorus, Inc. and Repligen Corporation.
- Review the Company's standard indemnification agreement terms for directors and officers.
- Check for any subsequent filings regarding the transition of the Chief Accounting Officer role.